F(ab')2 Ig Secondary Antibody | Ig secondary antibody

Goat F(ab')2 Anti-Human Ig-AP

Cat. Num. AAA679377

• Reactivity: Human
• Applications: ELISA, Immunohistochemistry
• Synonyms: F(ab')2 Ig; Polyclonal Secondary Antibody; Goat F(ab')2 Anti-Human Ig-AP; Ig secondary antibody

• Host: Goat
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: Goat F(ab')2 IgG
• Specificity: Reacts with the heavy and light chains of human IgG, IgM, and IgA
• Form/Format: 50mM Tris/1mM MgCl2/50% Glycerol containing <0.1% sodium azide, pH8.0

• Applicable Applications for Ig secondary antibody: ELISpot, Immunohistochemistry-Paraffin (IHC-P) Sections, Stimulation
• Application Notes: Quality tested applications for relevant formats include-; ELISA 1, 2, 5; FLISA; Flow Cytometry 7, 8; Other referenced applications for relevant formats include-; ELISpot 3, 4; Immunohistochemistry-Frozen Sections 6; Stimulation 9, 10
• Source: Pepsin digest of Goat Anti-Human Ig
• Conjugation: AP (Alkaline Phosphatase)
• Cross Adsorption: None; may react with immunoglobulins from other species
• Preparation and Storage: Store at 2-8 degree C. Please refer to product specific SDS

ELISA (EIA)

(ELISA plate was coated with purified human IgG, IgM, and IgA. Immunoglobulins were detected with serially diluted Goat F(ab')2 Anti-Human Ig-AP )

References

1. Kozlowski PA, Chen D, Eldridge JH, Jackson S. Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals. AIDS Res Hum Retroviruses. 1994;10:813-22. (ELISA)
2. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA. 2006;103:17408-13. (ELISA)
3. Sira MM, Yoshida T, Takeuchi M, Kashiwayama Y, Futatani T, Kanegane H, et al. A novel immunoregulatory protein in human colostrum, syntenin-1, for promoting the development of IgA-producing cells from cord blood B cells. Int Immunol. 2009;21:1013-23. (ELISpot)
4. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(4):R123. (ELISpot)
5. White CA, Pone EJ, Lam T, Tat C, Hayama KL, Li G, et al. Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. J Immunol. 2014;193:5933-50. (ELISA)
6. Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M, et al. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol. 2007;8:294-303. (IHC-FS)
7. Heile JM, Fong Y, Rosa D, Berger K, Saletti G, Campagnoli S, et al. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. J Virol. 2000;74:6885-92. (FC)
8. Bao G, Li Y, Ma Q, He X, Xing J, Yang X, et al. Isolating human antibody against human hepatocellular carcinoma by guided-selection. Cancer Biol Ther. 2005;4:1374-80. (FC)
9. Liubchenko GA, Appleberry HC, Striebich CC, Franklin KE, Derber LA, Holers VM, et al. Rheumatoid arthritis is associated with signaling alterations in naturally occurring autoreactive B-lymphocytes. J Autoimmun. 2013;40:111-21. (Stim)
10. Lyubchenko T, Zerbe GO. B cell receptor signaling-based index as a biomarker for the loss of peripheral immune tolerance in autoreactive B cells in rheumatoid arthritis. PLoS One. 2014;9(7):e102128. (Stim)